SEC filing · 8-K

Cingulate Inc.: Executive or director change

Cingulate extended the trial period for the full-time employment of Chief Medical Officer Matthew N. Brams to December 31, 2026.

Filed October 2, 2026

Neutral news

What happened

On September 30, 2026, subsidiary Cingulate Therapeutics LLC entered into Amendment No. 2 to the employment agreement with Matthew N. Brams, Executive Vice President and Chief Medical Officer.

The full interpretation is in the app

Why it matters, the key numbers from the document and what to watch next: the full interpretation of every report is part of Pro.

Read the full interpretation

Read the original

Filing document on SEC.gov All documents of this filing

Back to Cingulate Inc.

Summary generated automatically from the filing text and checked against it: every number above is printed in the document. It describes the filing and is not investment advice. Read the original before relying on it.